CL2015001371A1 - Proteínas de fusión de enzima lisosomal terapéutica objetivo y usos de las mismas - Google Patents
Proteínas de fusión de enzima lisosomal terapéutica objetivo y usos de las mismasInfo
- Publication number
- CL2015001371A1 CL2015001371A1 CL2015001371A CL2015001371A CL2015001371A1 CL 2015001371 A1 CL2015001371 A1 CL 2015001371A1 CL 2015001371 A CL2015001371 A CL 2015001371A CL 2015001371 A CL2015001371 A CL 2015001371A CL 2015001371 A1 CL2015001371 A1 CL 2015001371A1
- Authority
- CL
- Chile
- Prior art keywords
- fusion proteins
- lysosomal enzyme
- target therapeutic
- enzyme fusion
- therapeutic lysosomal
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002132 lysosomal effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730378P | 2012-11-27 | 2012-11-27 | |
| US201361788968P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001371A1 true CL2015001371A1 (es) | 2015-10-09 |
Family
ID=49753532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001371A CL2015001371A1 (es) | 2012-11-27 | 2015-05-20 | Proteínas de fusión de enzima lisosomal terapéutica objetivo y usos de las mismas |
Country Status (27)
| Country | Link |
|---|---|
| US (8) | US9376480B2 (es) |
| EP (2) | EP2925776B1 (es) |
| JP (2) | JP6831176B2 (es) |
| KR (4) | KR102262882B1 (es) |
| CN (1) | CN104822701B (es) |
| AR (1) | AR093626A1 (es) |
| AU (1) | AU2013352184B2 (es) |
| BR (1) | BR112015012152B1 (es) |
| CA (1) | CA2892146A1 (es) |
| CL (1) | CL2015001371A1 (es) |
| CY (1) | CY1122555T1 (es) |
| DK (2) | DK2925776T3 (es) |
| ES (2) | ES2729997T3 (es) |
| HK (1) | HK1216026A1 (es) |
| HR (2) | HRP20181351T1 (es) |
| HU (2) | HUE043679T2 (es) |
| IL (3) | IL238824B (es) |
| LT (1) | LT3115372T (es) |
| MX (2) | MX367024B (es) |
| PL (2) | PL2925776T3 (es) |
| PT (2) | PT2925776T (es) |
| RS (1) | RS58916B1 (es) |
| RU (1) | RU2680581C2 (es) |
| SI (1) | SI3115372T1 (es) |
| TW (2) | TWI711632B (es) |
| WO (1) | WO2014085621A1 (es) |
| ZA (1) | ZA201503509B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009244148B2 (en) | 2008-05-07 | 2014-10-09 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
| KR102262882B1 (ko) | 2012-11-27 | 2021-06-10 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 |
| KR20220119187A (ko) * | 2013-05-15 | 2022-08-26 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
| BR112017002741A2 (pt) * | 2014-08-11 | 2018-02-27 | Shire Human Genetic Therapies, Inc | peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas |
| WO2016049510A2 (en) * | 2014-09-25 | 2016-03-31 | The General Hospital Corporation | Cell-based targeted delivery of pseudonomas exotoxin |
| WO2016065319A1 (en) * | 2014-10-24 | 2016-04-28 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting of enzymes, and uses thereof |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| JP2018538008A (ja) | 2015-11-06 | 2018-12-27 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム酵素の取り込みを中和する抗体または他の因子の検出のための細胞ベースアッセイ |
| KR20180114199A (ko) * | 2016-02-24 | 2018-10-17 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들, 관련 제형들 및 이의 용도들 |
| BR112018071156A2 (pt) | 2016-04-15 | 2019-03-12 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
| CL2016003282A1 (es) | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
| EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
| EP3762505A4 (en) * | 2018-03-09 | 2021-12-01 | Avrobio, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR PARKINSON'S DISEASE |
| JP2021521851A (ja) | 2018-04-30 | 2021-08-30 | アミカス セラピューティックス インコーポレイテッド | 遺伝子治療構築物及び使用方法 |
| EP3802619A1 (en) | 2018-06-08 | 2021-04-14 | F. Hoffmann-La Roche AG | Peptidic linker with reduced post-translational modification |
| SG11202103640VA (en) | 2018-10-10 | 2021-05-28 | Amicus Therapeutics Inc | Disulfide bond stabilized polypeptide compositions and methods of use |
| WO2020102667A2 (en) * | 2018-11-16 | 2020-05-22 | Asklepios Biopharmaceutical, Inc. | Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence |
| CN115087458A (zh) * | 2019-10-10 | 2022-09-20 | 阿米库斯治疗学公司 | 变体igf2构建体 |
| WO2021183895A1 (en) | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| CN115975039A (zh) * | 2021-10-15 | 2023-04-18 | 中山大学 | 重组融合抗体和抗体-药物偶联物及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| AUPN674895A0 (en) | 1995-11-23 | 1995-12-14 | Women's And Children's Hospital | Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| DE10035433C2 (de) | 2000-07-20 | 2002-07-18 | Tuma Wolfgang | Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003032727A1 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| CA2487815A1 (en) | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| JP4914224B2 (ja) | 2004-02-10 | 2012-04-11 | バイオマリン ファーマシューティカル インコーポレイテッド | 酸性αグルコシダーゼおよびそのフラグメント |
| AU2006220709B2 (en) | 2005-03-04 | 2012-09-06 | Biogen Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| AU2009244148B2 (en) * | 2008-05-07 | 2014-10-09 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
| US8697654B2 (en) * | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
| US9029530B2 (en) | 2009-01-02 | 2015-05-12 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
| EP3075386B1 (en) * | 2009-06-17 | 2019-10-16 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| MX2013000324A (es) * | 2010-06-25 | 2013-02-01 | Shire Human Genetic Therapies | Tratamiento del sindrome de sanfilippo tipo b. |
| BR112012032777B1 (pt) | 2010-06-25 | 2020-10-27 | Amcor Rigid Plastics Usa, Llc. | sistema de remoção de oxigênio para um recipiente |
| WO2012088461A2 (en) * | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Linker peptides and polypeptides comprising same |
| WO2012122042A2 (en) * | 2011-03-04 | 2012-09-13 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| US9409958B2 (en) * | 2011-03-10 | 2016-08-09 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| KR102262882B1 (ko) | 2012-11-27 | 2021-06-10 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 |
-
2013
- 2013-11-27 KR KR1020157017224A patent/KR102262882B1/ko active IP Right Grant
- 2013-11-27 RU RU2015125491A patent/RU2680581C2/ru active
- 2013-11-27 MX MX2015006644A patent/MX367024B/es active IP Right Grant
- 2013-11-27 BR BR112015012152-7A patent/BR112015012152B1/pt active IP Right Grant
- 2013-11-27 HU HUE16182420A patent/HUE043679T2/hu unknown
- 2013-11-27 AU AU2013352184A patent/AU2013352184B2/en active Active
- 2013-11-27 SI SI201331450T patent/SI3115372T1/sl unknown
- 2013-11-27 JP JP2015544209A patent/JP6831176B2/ja active Active
- 2013-11-27 EP EP13802834.5A patent/EP2925776B1/en active Active
- 2013-11-27 RS RS20190585A patent/RS58916B1/sr unknown
- 2013-11-27 PT PT138028345T patent/PT2925776T/pt unknown
- 2013-11-27 HU HUE13802834A patent/HUE039334T2/hu unknown
- 2013-11-27 ES ES16182420T patent/ES2729997T3/es active Active
- 2013-11-27 PL PL13802834T patent/PL2925776T3/pl unknown
- 2013-11-27 KR KR1020237012007A patent/KR20230054482A/ko not_active Application Discontinuation
- 2013-11-27 DK DK13802834.5T patent/DK2925776T3/en active
- 2013-11-27 PT PT16182420T patent/PT3115372T/pt unknown
- 2013-11-27 WO PCT/US2013/072287 patent/WO2014085621A1/en active Application Filing
- 2013-11-27 US US14/092,336 patent/US9376480B2/en active Active
- 2013-11-27 DK DK16182420.6T patent/DK3115372T3/da active
- 2013-11-27 CA CA2892146A patent/CA2892146A1/en active Pending
- 2013-11-27 KR KR1020227011416A patent/KR102521039B1/ko active IP Right Grant
- 2013-11-27 LT LTEP16182420.6T patent/LT3115372T/lt unknown
- 2013-11-27 PL PL16182420T patent/PL3115372T3/pl unknown
- 2013-11-27 KR KR1020217017007A patent/KR102385392B1/ko active IP Right Grant
- 2013-11-27 CN CN201380061935.4A patent/CN104822701B/zh active Active
- 2013-11-27 TW TW107114660A patent/TWI711632B/zh active
- 2013-11-27 EP EP16182420.6A patent/EP3115372B1/en active Active
- 2013-11-27 AR ARP130104367A patent/AR093626A1/es active IP Right Grant
- 2013-11-27 ES ES13802834.5T patent/ES2679374T3/es active Active
- 2013-11-27 TW TW102143329A patent/TWI626250B/zh active
-
2015
- 2015-05-14 IL IL238824A patent/IL238824B/en active IP Right Grant
- 2015-05-19 ZA ZA2015/03509A patent/ZA201503509B/en unknown
- 2015-05-20 CL CL2015001371A patent/CL2015001371A1/es unknown
- 2015-05-26 MX MX2019009191A patent/MX2019009191A/es active IP Right Grant
- 2015-10-14 US US14/883,193 patent/US9834587B2/en active Active
- 2015-10-14 US US14/883,169 patent/US9845346B2/en active Active
- 2015-10-14 US US14/883,211 patent/US9771408B2/en active Active
- 2015-10-14 US US14/883,203 patent/US9834588B2/en active Active
-
2016
- 2016-04-06 HK HK16103915.8A patent/HK1216026A1/zh unknown
-
2017
- 2017-08-28 US US15/688,438 patent/US10301369B2/en active Active
-
2018
- 2018-08-23 HR HRP20181351TT patent/HRP20181351T1/hr unknown
- 2018-11-13 IL IL262976A patent/IL262976B/en active IP Right Grant
-
2019
- 2019-04-08 US US16/378,163 patent/US11254725B2/en active Active
- 2019-05-17 HR HRP20190918TT patent/HRP20190918T1/hr unknown
- 2019-06-06 CY CY20191100600T patent/CY1122555T1/el unknown
- 2019-07-24 JP JP2019136013A patent/JP6913719B2/ja active Active
-
2020
- 2020-02-23 IL IL272854A patent/IL272854B/en unknown
-
2022
- 2022-01-10 US US17/572,018 patent/US20220127326A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015001371A1 (es) | Proteínas de fusión de enzima lisosomal terapéutica objetivo y usos de las mismas | |
| CL2014003605A1 (es) | Proteínas de fusión de interleuquina-10 y usos de las mismas | |
| BR112014000055A2 (pt) | polipeptídeos de fusão de relaxina e usos dos mesmos | |
| DK3744835T3 (da) | Dna modificerende fusionsproteiner og metoder til anvendelse deraf | |
| DK3489254T3 (da) | Målrettede/immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf | |
| BR112014004213A2 (pt) | novas moléculas de fusão kif5b-ret e usos das mesmas | |
| BR112015002790A2 (pt) | anticorpos asgpr e usos dos mesmos. | |
| BR112013021524A2 (pt) | micro-organismos recombinantes e usos dos mesmos | |
| DK3321287T3 (da) | Fusionsproteiner og kombinationsvacciner | |
| CL2015001321A1 (es) | Anticuerpos anti-ceacam5 y usos de éstos | |
| BR112013007499A2 (pt) | piridazinonas - métodos de criação e usos | |
| BR112015003838A2 (pt) | formulações de anticorpo e proteína | |
| CL2014000927A1 (es) | Proteinas naglu humana recombinante y usos de la misma | |
| EP2877854A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
| BR112015001459A2 (pt) | anticorpos anti-kit e usos dos mesmos. | |
| DK3434775T3 (da) | Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf | |
| BR112015011111A2 (pt) | proteína multifuncional e formulação farmacêutica | |
| DK2914630T3 (da) | Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft | |
| CL2016000219A1 (es) | Proteinas de fusión terapéutica. | |
| BR112014030716A2 (pt) | fragmentos de fibronectina modificada ou variantes e usos dos mesmos | |
| BR112013013548A2 (pt) | proteína de fusão anticancerígena | |
| DK2782598T3 (da) | Rekombinante proteiner og terapeutiske anvendelser deraf | |
| DK3173102T3 (da) | FGFR-FC-fusionsprotein og anvendelse deraf | |
| EP2930189A4 (en) | CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF | |
| BR112014002290A2 (pt) | vírus recombinante de influenza suína e usos do mesmo |